nodes	percent_of_prediction	percent_of_DWPC	metapath
Imipramine—ORM1—Vandetanib—thyroid cancer	0.19	0.297	CbGbCtD
Imipramine—HTR2C—Sorafenib—thyroid cancer	0.0793	0.124	CbGbCtD
Imipramine—CYP3A7—Sorafenib—thyroid cancer	0.0517	0.0807	CbGbCtD
Imipramine—CYP3A7-CYP3A51P—Sorafenib—thyroid cancer	0.0517	0.0807	CbGbCtD
Imipramine—CYP2B6—Sorafenib—thyroid cancer	0.0492	0.0769	CbGbCtD
Imipramine—CYP2C19—Sorafenib—thyroid cancer	0.0313	0.0489	CbGbCtD
Imipramine—CYP2B6—Doxorubicin—thyroid cancer	0.0299	0.0466	CbGbCtD
Imipramine—CYP1A2—Sorafenib—thyroid cancer	0.0289	0.0451	CbGbCtD
Imipramine—ABCB1—Sorafenib—thyroid cancer	0.0252	0.0394	CbGbCtD
Imipramine—CYP3A4—Vandetanib—thyroid cancer	0.0251	0.0392	CbGbCtD
Imipramine—CYP2D6—Sorafenib—thyroid cancer	0.0238	0.0371	CbGbCtD
Imipramine—ABCB1—Doxorubicin—thyroid cancer	0.0153	0.0239	CbGbCtD
Imipramine—CYP3A4—Sorafenib—thyroid cancer	0.0151	0.0236	CbGbCtD
Imipramine—CYP2D6—Doxorubicin—thyroid cancer	0.0144	0.0225	CbGbCtD
Imipramine—CYP3A4—Doxorubicin—thyroid cancer	0.00917	0.0143	CbGbCtD
Imipramine—SLC22A4—larynx—thyroid cancer	0.00793	0.143	CbGeAlD
Imipramine—SLC22A4—neck—thyroid cancer	0.0021	0.0379	CbGeAlD
Imipramine—KCND2—head—thyroid cancer	0.00193	0.0348	CbGeAlD
Imipramine—KCND3—thyroid gland—thyroid cancer	0.0019	0.0342	CbGeAlD
Imipramine—KCND3—head—thyroid cancer	0.00168	0.0303	CbGeAlD
Imipramine—CHRM4—head—thyroid cancer	0.0016	0.0289	CbGeAlD
Imipramine—HTR7—neck—thyroid cancer	0.00158	0.0285	CbGeAlD
Imipramine—SLC22A3—saliva-secreting gland—thyroid cancer	0.00149	0.0269	CbGeAlD
Imipramine—CHRM1—saliva-secreting gland—thyroid cancer	0.00145	0.0261	CbGeAlD
Imipramine—HTR6—head—thyroid cancer	0.00144	0.0258	CbGeAlD
Imipramine—CHRM3—saliva-secreting gland—thyroid cancer	0.00129	0.0233	CbGeAlD
Imipramine—SLC22A4—trachea—thyroid cancer	0.00127	0.0228	CbGeAlD
Imipramine—CHRM5—head—thyroid cancer	0.00125	0.0226	CbGeAlD
Imipramine—KCND3—lymph node—thyroid cancer	0.00118	0.0212	CbGeAlD
Imipramine—ADRA1B—head—thyroid cancer	0.00115	0.0206	CbGeAlD
Imipramine—ADRA1D—head—thyroid cancer	0.00112	0.0202	CbGeAlD
Imipramine—CHRM1—trachea—thyroid cancer	0.00112	0.0201	CbGeAlD
Imipramine—SLC22A4—thyroid gland—thyroid cancer	0.001	0.018	CbGeAlD
Imipramine—HTR2A—neck—thyroid cancer	0.000985	0.0177	CbGeAlD
Imipramine—HTR7—trachea—thyroid cancer	0.000951	0.0171	CbGeAlD
Imipramine—SLC22A3—thyroid gland—thyroid cancer	0.000911	0.0164	CbGeAlD
Imipramine—Dermatitis atopic—Doxorubicin—thyroid cancer	0.000887	0.00404	CcSEcCtD
Imipramine—Decreased appetite—Vandetanib—thyroid cancer	0.000882	0.00402	CcSEcCtD
Imipramine—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.000876	0.004	CcSEcCtD
Imipramine—Fatigue—Vandetanib—thyroid cancer	0.000875	0.00399	CcSEcCtD
Imipramine—Angiopathy—Sorafenib—thyroid cancer	0.000874	0.00399	CcSEcCtD
Imipramine—Immune system disorder—Sorafenib—thyroid cancer	0.00087	0.00397	CcSEcCtD
Imipramine—Mediastinal disorder—Sorafenib—thyroid cancer	0.000868	0.00396	CcSEcCtD
Imipramine—Constipation—Vandetanib—thyroid cancer	0.000868	0.00396	CcSEcCtD
Imipramine—Petechiae—Epirubicin—thyroid cancer	0.000862	0.00393	CcSEcCtD
Imipramine—Arrhythmia—Sorafenib—thyroid cancer	0.000861	0.00393	CcSEcCtD
Imipramine—CHRM2—head—thyroid cancer	0.000861	0.0155	CbGeAlD
Imipramine—SLC6A3—head—thyroid cancer	0.000858	0.0155	CbGeAlD
Imipramine—Alopecia—Sorafenib—thyroid cancer	0.000852	0.00388	CcSEcCtD
Imipramine—SLC22A1—head—thyroid cancer	0.000845	0.0152	CbGeAlD
Imipramine—Mental disorder—Sorafenib—thyroid cancer	0.000844	0.00385	CcSEcCtD
Imipramine—Malnutrition—Sorafenib—thyroid cancer	0.000839	0.00383	CcSEcCtD
Imipramine—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00083	0.00379	CcSEcCtD
Imipramine—HTR2C—head—thyroid cancer	0.00083	0.0149	CbGeAlD
Imipramine—Delirium—Epirubicin—thyroid cancer	0.000825	0.00376	CcSEcCtD
Imipramine—Dysgeusia—Sorafenib—thyroid cancer	0.000821	0.00375	CcSEcCtD
Imipramine—SLC22A3—head—thyroid cancer	0.000808	0.0145	CbGeAlD
Imipramine—Body temperature increased—Vandetanib—thyroid cancer	0.000802	0.00366	CcSEcCtD
Imipramine—Abdominal pain—Vandetanib—thyroid cancer	0.000802	0.00366	CcSEcCtD
Imipramine—Petechiae—Doxorubicin—thyroid cancer	0.000798	0.00364	CcSEcCtD
Imipramine—CHRM3—thyroid gland—thyroid cancer	0.00079	0.0142	CbGeAlD
Imipramine—SLC6A4—head—thyroid cancer	0.000786	0.0142	CbGeAlD
Imipramine—CHRM1—head—thyroid cancer	0.000783	0.0141	CbGeAlD
Imipramine—Delirium—Doxorubicin—thyroid cancer	0.000763	0.00348	CcSEcCtD
Imipramine—Syncope—Sorafenib—thyroid cancer	0.000752	0.00343	CcSEcCtD
Imipramine—Leukopenia—Sorafenib—thyroid cancer	0.000751	0.00343	CcSEcCtD
Imipramine—Loss of consciousness—Sorafenib—thyroid cancer	0.000737	0.00336	CcSEcCtD
Imipramine—Atrioventricular block—Epirubicin—thyroid cancer	0.000731	0.00334	CcSEcCtD
Imipramine—Asthenia—Vandetanib—thyroid cancer	0.000728	0.00332	CcSEcCtD
Imipramine—Hypertension—Sorafenib—thyroid cancer	0.000724	0.0033	CcSEcCtD
Imipramine—Coordination abnormal—Epirubicin—thyroid cancer	0.000722	0.00329	CcSEcCtD
Imipramine—Pruritus—Vandetanib—thyroid cancer	0.000718	0.00328	CcSEcCtD
Imipramine—HRH1—trachea—thyroid cancer	0.00071	0.0128	CbGeAlD
Imipramine—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.000709	0.00324	CcSEcCtD
Imipramine—Ventricular tachycardia—Epirubicin—thyroid cancer	0.000709	0.00324	CcSEcCtD
Imipramine—CHRM3—head—thyroid cancer	0.000701	0.0126	CbGeAlD
Imipramine—Dry mouth—Sorafenib—thyroid cancer	0.000698	0.00319	CcSEcCtD
Imipramine—HTR1A—head—thyroid cancer	0.000698	0.0126	CbGeAlD
Imipramine—Diarrhoea—Vandetanib—thyroid cancer	0.000694	0.00317	CcSEcCtD
Imipramine—SLC6A2—head—thyroid cancer	0.000692	0.0125	CbGeAlD
Imipramine—Anaphylactic shock—Sorafenib—thyroid cancer	0.000685	0.00312	CcSEcCtD
Imipramine—Infection—Sorafenib—thyroid cancer	0.00068	0.0031	CcSEcCtD
Imipramine—Atrioventricular block—Doxorubicin—thyroid cancer	0.000677	0.00309	CcSEcCtD
Imipramine—Shock—Sorafenib—thyroid cancer	0.000674	0.00307	CcSEcCtD
Imipramine—Nervous system disorder—Sorafenib—thyroid cancer	0.000671	0.00306	CcSEcCtD
Imipramine—Dizziness—Vandetanib—thyroid cancer	0.000671	0.00306	CcSEcCtD
Imipramine—Thrombocytopenia—Sorafenib—thyroid cancer	0.00067	0.00306	CcSEcCtD
Imipramine—Coordination abnormal—Doxorubicin—thyroid cancer	0.000668	0.00305	CcSEcCtD
Imipramine—HTR7—head—thyroid cancer	0.000667	0.012	CbGeAlD
Imipramine—Skin disorder—Sorafenib—thyroid cancer	0.000665	0.00303	CcSEcCtD
Imipramine—Ventricular tachycardia—Doxorubicin—thyroid cancer	0.000656	0.00299	CcSEcCtD
Imipramine—Anorexia—Sorafenib—thyroid cancer	0.000653	0.00298	CcSEcCtD
Imipramine—ORM1—lymph node—thyroid cancer	0.000646	0.0116	CbGeAlD
Imipramine—Vomiting—Vandetanib—thyroid cancer	0.000645	0.00294	CcSEcCtD
Imipramine—ADRA1A—head—thyroid cancer	0.000644	0.0116	CbGeAlD
Imipramine—Rash—Vandetanib—thyroid cancer	0.00064	0.00292	CcSEcCtD
Imipramine—Dermatitis—Vandetanib—thyroid cancer	0.000639	0.00292	CcSEcCtD
Imipramine—Headache—Vandetanib—thyroid cancer	0.000636	0.0029	CcSEcCtD
Imipramine—DRD2—head—thyroid cancer	0.000631	0.0114	CbGeAlD
Imipramine—SLC22A4—lymph node—thyroid cancer	0.000622	0.0112	CbGeAlD
Imipramine—KCNH2—head—thyroid cancer	0.000622	0.0112	CbGeAlD
Imipramine—Nausea—Vandetanib—thyroid cancer	0.000603	0.00275	CcSEcCtD
Imipramine—Dyspepsia—Sorafenib—thyroid cancer	0.000603	0.00275	CcSEcCtD
Imipramine—CYP1A2—thyroid gland—thyroid cancer	0.0006	0.0108	CbGeAlD
Imipramine—Decreased appetite—Sorafenib—thyroid cancer	0.000595	0.00271	CcSEcCtD
Imipramine—HTR2A—trachea—thyroid cancer	0.000593	0.0107	CbGeAlD
Imipramine—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.000591	0.0027	CcSEcCtD
Imipramine—Fatigue—Sorafenib—thyroid cancer	0.00059	0.00269	CcSEcCtD
Imipramine—Constipation—Sorafenib—thyroid cancer	0.000585	0.00267	CcSEcCtD
Imipramine—Vascular purpura—Epirubicin—thyroid cancer	0.000575	0.00262	CcSEcCtD
Imipramine—Cardiac failure congestive—Epirubicin—thyroid cancer	0.000568	0.00259	CcSEcCtD
Imipramine—SLC22A3—lymph node—thyroid cancer	0.000566	0.0102	CbGeAlD
Imipramine—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00056	0.00255	CcSEcCtD
Imipramine—Hot flush—Epirubicin—thyroid cancer	0.00055	0.00251	CcSEcCtD
Imipramine—Menopausal symptoms—Epirubicin—thyroid cancer	0.000546	0.00249	CcSEcCtD
Imipramine—Urticaria—Sorafenib—thyroid cancer	0.000544	0.00248	CcSEcCtD
Imipramine—Abdominal pain—Sorafenib—thyroid cancer	0.000541	0.00247	CcSEcCtD
Imipramine—Body temperature increased—Sorafenib—thyroid cancer	0.000541	0.00247	CcSEcCtD
Imipramine—CYP2E1—thyroid gland—thyroid cancer	0.00054	0.00972	CbGeAlD
Imipramine—Purpura—Epirubicin—thyroid cancer	0.000534	0.00244	CcSEcCtD
Imipramine—Vascular purpura—Doxorubicin—thyroid cancer	0.000532	0.00243	CcSEcCtD
Imipramine—Cardiac failure—Epirubicin—thyroid cancer	0.000528	0.00241	CcSEcCtD
Imipramine—Cerebrovascular accident—Epirubicin—thyroid cancer	0.000525	0.0024	CcSEcCtD
Imipramine—Cardiac failure congestive—Doxorubicin—thyroid cancer	0.000525	0.0024	CcSEcCtD
Imipramine—CYP2B6—head—thyroid cancer	0.00051	0.00919	CbGeAlD
Imipramine—Hot flush—Doxorubicin—thyroid cancer	0.000509	0.00232	CcSEcCtD
Imipramine—Affect lability—Epirubicin—thyroid cancer	0.000507	0.00231	CcSEcCtD
Imipramine—Menopausal symptoms—Doxorubicin—thyroid cancer	0.000505	0.0023	CcSEcCtD
Imipramine—HRH1—head—thyroid cancer	0.000498	0.00897	CbGeAlD
Imipramine—Purpura—Doxorubicin—thyroid cancer	0.000494	0.00225	CcSEcCtD
Imipramine—Asthenia—Sorafenib—thyroid cancer	0.000491	0.00224	CcSEcCtD
Imipramine—Cardiac failure—Doxorubicin—thyroid cancer	0.000488	0.00223	CcSEcCtD
Imipramine—Mood swings—Epirubicin—thyroid cancer	0.000488	0.00222	CcSEcCtD
Imipramine—Cerebrovascular accident—Doxorubicin—thyroid cancer	0.000486	0.00222	CcSEcCtD
Imipramine—SLC6A2—lymph node—thyroid cancer	0.000485	0.00873	CbGeAlD
Imipramine—Pruritus—Sorafenib—thyroid cancer	0.000484	0.00221	CcSEcCtD
Imipramine—Ataxia—Epirubicin—thyroid cancer	0.000484	0.00221	CcSEcCtD
Imipramine—CYP2E1—head—thyroid cancer	0.000479	0.00862	CbGeAlD
Imipramine—Liver function test abnormal—Epirubicin—thyroid cancer	0.000475	0.00217	CcSEcCtD
Imipramine—Orthostatic hypotension—Epirubicin—thyroid cancer	0.00047	0.00214	CcSEcCtD
Imipramine—Affect lability—Doxorubicin—thyroid cancer	0.000469	0.00214	CcSEcCtD
Imipramine—Diarrhoea—Sorafenib—thyroid cancer	0.000468	0.00214	CcSEcCtD
Imipramine—Breast disorder—Epirubicin—thyroid cancer	0.000465	0.00212	CcSEcCtD
Imipramine—Dizziness—Sorafenib—thyroid cancer	0.000453	0.00207	CcSEcCtD
Imipramine—Mood swings—Doxorubicin—thyroid cancer	0.000451	0.00206	CcSEcCtD
Imipramine—Ataxia—Doxorubicin—thyroid cancer	0.000448	0.00204	CcSEcCtD
Imipramine—Eosinophilia—Epirubicin—thyroid cancer	0.000441	0.00201	CcSEcCtD
Imipramine—Liver function test abnormal—Doxorubicin—thyroid cancer	0.00044	0.00201	CcSEcCtD
Imipramine—Vomiting—Sorafenib—thyroid cancer	0.000435	0.00199	CcSEcCtD
Imipramine—KCNH2—lymph node—thyroid cancer	0.000435	0.00784	CbGeAlD
Imipramine—Orthostatic hypotension—Doxorubicin—thyroid cancer	0.000435	0.00198	CcSEcCtD
Imipramine—Rash—Sorafenib—thyroid cancer	0.000432	0.00197	CcSEcCtD
Imipramine—Dermatitis—Sorafenib—thyroid cancer	0.000431	0.00197	CcSEcCtD
Imipramine—Breast disorder—Doxorubicin—thyroid cancer	0.00043	0.00196	CcSEcCtD
Imipramine—Headache—Sorafenib—thyroid cancer	0.000429	0.00196	CcSEcCtD
Imipramine—Pancytopenia—Epirubicin—thyroid cancer	0.000423	0.00193	CcSEcCtD
Imipramine—HTR2A—head—thyroid cancer	0.000416	0.00749	CbGeAlD
Imipramine—Pollakiuria—Epirubicin—thyroid cancer	0.000411	0.00187	CcSEcCtD
Imipramine—Eosinophilia—Doxorubicin—thyroid cancer	0.000408	0.00186	CcSEcCtD
Imipramine—Nausea—Sorafenib—thyroid cancer	0.000407	0.00185	CcSEcCtD
Imipramine—Photosensitivity reaction—Epirubicin—thyroid cancer	0.000406	0.00185	CcSEcCtD
Imipramine—Weight increased—Epirubicin—thyroid cancer	0.000405	0.00185	CcSEcCtD
Imipramine—Weight decreased—Epirubicin—thyroid cancer	0.000403	0.00184	CcSEcCtD
Imipramine—Drowsiness—Epirubicin—thyroid cancer	0.000397	0.00181	CcSEcCtD
Imipramine—Infestation—Epirubicin—thyroid cancer	0.000397	0.00181	CcSEcCtD
Imipramine—Infestation NOS—Epirubicin—thyroid cancer	0.000397	0.00181	CcSEcCtD
Imipramine—Pancytopenia—Doxorubicin—thyroid cancer	0.000391	0.00178	CcSEcCtD
Imipramine—Neuropathy peripheral—Epirubicin—thyroid cancer	0.000389	0.00177	CcSEcCtD
Imipramine—ABCB1—trachea—thyroid cancer	0.000389	0.007	CbGeAlD
Imipramine—Stomatitis—Epirubicin—thyroid cancer	0.000387	0.00176	CcSEcCtD
Imipramine—Jaundice—Epirubicin—thyroid cancer	0.000387	0.00176	CcSEcCtD
Imipramine—Pollakiuria—Doxorubicin—thyroid cancer	0.00038	0.00173	CcSEcCtD
Imipramine—CYP2D6—head—thyroid cancer	0.000379	0.00683	CbGeAlD
Imipramine—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.000376	0.00171	CcSEcCtD
Imipramine—Hepatobiliary disease—Epirubicin—thyroid cancer	0.000375	0.00171	CcSEcCtD
Imipramine—Weight increased—Doxorubicin—thyroid cancer	0.000375	0.00171	CcSEcCtD
Imipramine—Weight decreased—Doxorubicin—thyroid cancer	0.000372	0.0017	CcSEcCtD
Imipramine—Agranulocytosis—Epirubicin—thyroid cancer	0.00037	0.00169	CcSEcCtD
Imipramine—Infestation—Doxorubicin—thyroid cancer	0.000367	0.00167	CcSEcCtD
Imipramine—Drowsiness—Doxorubicin—thyroid cancer	0.000367	0.00167	CcSEcCtD
Imipramine—Infestation NOS—Doxorubicin—thyroid cancer	0.000367	0.00167	CcSEcCtD
Imipramine—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.00036	0.00164	CcSEcCtD
Imipramine—Jaundice—Doxorubicin—thyroid cancer	0.000358	0.00163	CcSEcCtD
Imipramine—Stomatitis—Doxorubicin—thyroid cancer	0.000358	0.00163	CcSEcCtD
Imipramine—Hepatitis—Epirubicin—thyroid cancer	0.000356	0.00162	CcSEcCtD
Imipramine—Hypoaesthesia—Epirubicin—thyroid cancer	0.000354	0.00162	CcSEcCtD
Imipramine—Urinary tract disorder—Epirubicin—thyroid cancer	0.000352	0.0016	CcSEcCtD
Imipramine—Urethral disorder—Epirubicin—thyroid cancer	0.000349	0.00159	CcSEcCtD
Imipramine—HRH1—lymph node—thyroid cancer	0.000349	0.00628	CbGeAlD
Imipramine—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.000347	0.00158	CcSEcCtD
Imipramine—Agranulocytosis—Doxorubicin—thyroid cancer	0.000343	0.00156	CcSEcCtD
Imipramine—Eye disorder—Epirubicin—thyroid cancer	0.000333	0.00152	CcSEcCtD
Imipramine—Tinnitus—Epirubicin—thyroid cancer	0.000332	0.00151	CcSEcCtD
Imipramine—Flushing—Epirubicin—thyroid cancer	0.000331	0.00151	CcSEcCtD
Imipramine—Cardiac disorder—Epirubicin—thyroid cancer	0.000331	0.00151	CcSEcCtD
Imipramine—Hepatitis—Doxorubicin—thyroid cancer	0.00033	0.0015	CcSEcCtD
Imipramine—Hypoaesthesia—Doxorubicin—thyroid cancer	0.000328	0.0015	CcSEcCtD
Imipramine—Urinary tract disorder—Doxorubicin—thyroid cancer	0.000325	0.00148	CcSEcCtD
Imipramine—Angiopathy—Epirubicin—thyroid cancer	0.000323	0.00147	CcSEcCtD
Imipramine—Urethral disorder—Doxorubicin—thyroid cancer	0.000323	0.00147	CcSEcCtD
Imipramine—Immune system disorder—Epirubicin—thyroid cancer	0.000322	0.00147	CcSEcCtD
Imipramine—Mediastinal disorder—Epirubicin—thyroid cancer	0.000321	0.00146	CcSEcCtD
Imipramine—Arrhythmia—Epirubicin—thyroid cancer	0.000318	0.00145	CcSEcCtD
Imipramine—Alopecia—Epirubicin—thyroid cancer	0.000315	0.00144	CcSEcCtD
Imipramine—Mental disorder—Epirubicin—thyroid cancer	0.000312	0.00142	CcSEcCtD
Imipramine—Malnutrition—Epirubicin—thyroid cancer	0.00031	0.00141	CcSEcCtD
Imipramine—Eye disorder—Doxorubicin—thyroid cancer	0.000308	0.0014	CcSEcCtD
Imipramine—ABCB1—thyroid gland—thyroid cancer	0.000307	0.00553	CbGeAlD
Imipramine—Tinnitus—Doxorubicin—thyroid cancer	0.000307	0.0014	CcSEcCtD
Imipramine—Flushing—Doxorubicin—thyroid cancer	0.000306	0.0014	CcSEcCtD
Imipramine—Cardiac disorder—Doxorubicin—thyroid cancer	0.000306	0.0014	CcSEcCtD
Imipramine—Tension—Epirubicin—thyroid cancer	0.000304	0.00139	CcSEcCtD
Imipramine—Dysgeusia—Epirubicin—thyroid cancer	0.000304	0.00138	CcSEcCtD
Imipramine—Nervousness—Epirubicin—thyroid cancer	0.000301	0.00137	CcSEcCtD
Imipramine—Angiopathy—Doxorubicin—thyroid cancer	0.000299	0.00136	CcSEcCtD
Imipramine—Immune system disorder—Doxorubicin—thyroid cancer	0.000298	0.00136	CcSEcCtD
Imipramine—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000297	0.00135	CcSEcCtD
Imipramine—Arrhythmia—Doxorubicin—thyroid cancer	0.000294	0.00134	CcSEcCtD
Imipramine—Vision blurred—Epirubicin—thyroid cancer	0.000292	0.00133	CcSEcCtD
Imipramine—Alopecia—Doxorubicin—thyroid cancer	0.000291	0.00133	CcSEcCtD
Imipramine—Mental disorder—Doxorubicin—thyroid cancer	0.000289	0.00132	CcSEcCtD
Imipramine—Ill-defined disorder—Epirubicin—thyroid cancer	0.000288	0.00131	CcSEcCtD
Imipramine—Malnutrition—Doxorubicin—thyroid cancer	0.000287	0.00131	CcSEcCtD
Imipramine—Agitation—Epirubicin—thyroid cancer	0.000285	0.0013	CcSEcCtD
Imipramine—Tension—Doxorubicin—thyroid cancer	0.000281	0.00128	CcSEcCtD
Imipramine—Dysgeusia—Doxorubicin—thyroid cancer	0.000281	0.00128	CcSEcCtD
Imipramine—Malaise—Epirubicin—thyroid cancer	0.00028	0.00128	CcSEcCtD
Imipramine—Nervousness—Doxorubicin—thyroid cancer	0.000279	0.00127	CcSEcCtD
Imipramine—Syncope—Epirubicin—thyroid cancer	0.000278	0.00127	CcSEcCtD
Imipramine—Leukopenia—Epirubicin—thyroid cancer	0.000278	0.00127	CcSEcCtD
Imipramine—Palpitations—Epirubicin—thyroid cancer	0.000274	0.00125	CcSEcCtD
Imipramine—ABCB1—head—thyroid cancer	0.000273	0.00491	CbGeAlD
Imipramine—Loss of consciousness—Epirubicin—thyroid cancer	0.000272	0.00124	CcSEcCtD
Imipramine—Vision blurred—Doxorubicin—thyroid cancer	0.00027	0.00123	CcSEcCtD
Imipramine—Convulsion—Epirubicin—thyroid cancer	0.000269	0.00123	CcSEcCtD
Imipramine—Hypertension—Epirubicin—thyroid cancer	0.000268	0.00122	CcSEcCtD
Imipramine—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000266	0.00121	CcSEcCtD
Imipramine—Agitation—Doxorubicin—thyroid cancer	0.000264	0.0012	CcSEcCtD
Imipramine—Anxiety—Epirubicin—thyroid cancer	0.000263	0.0012	CcSEcCtD
Imipramine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000262	0.0012	CcSEcCtD
Imipramine—Discomfort—Epirubicin—thyroid cancer	0.000261	0.00119	CcSEcCtD
Imipramine—Malaise—Doxorubicin—thyroid cancer	0.000259	0.00118	CcSEcCtD
Imipramine—Dry mouth—Epirubicin—thyroid cancer	0.000258	0.00118	CcSEcCtD
Imipramine—Syncope—Doxorubicin—thyroid cancer	0.000257	0.00117	CcSEcCtD
Imipramine—Leukopenia—Doxorubicin—thyroid cancer	0.000257	0.00117	CcSEcCtD
Imipramine—Confusional state—Epirubicin—thyroid cancer	0.000255	0.00116	CcSEcCtD
Imipramine—Palpitations—Doxorubicin—thyroid cancer	0.000254	0.00116	CcSEcCtD
Imipramine—Anaphylactic shock—Epirubicin—thyroid cancer	0.000253	0.00115	CcSEcCtD
Imipramine—Oedema—Epirubicin—thyroid cancer	0.000253	0.00115	CcSEcCtD
Imipramine—Loss of consciousness—Doxorubicin—thyroid cancer	0.000252	0.00115	CcSEcCtD
Imipramine—Infection—Epirubicin—thyroid cancer	0.000251	0.00115	CcSEcCtD
Imipramine—Shock—Epirubicin—thyroid cancer	0.000249	0.00114	CcSEcCtD
Imipramine—Convulsion—Doxorubicin—thyroid cancer	0.000249	0.00113	CcSEcCtD
Imipramine—Nervous system disorder—Epirubicin—thyroid cancer	0.000248	0.00113	CcSEcCtD
Imipramine—Thrombocytopenia—Epirubicin—thyroid cancer	0.000248	0.00113	CcSEcCtD
Imipramine—Hypertension—Doxorubicin—thyroid cancer	0.000248	0.00113	CcSEcCtD
Imipramine—Tachycardia—Epirubicin—thyroid cancer	0.000247	0.00113	CcSEcCtD
Imipramine—Skin disorder—Epirubicin—thyroid cancer	0.000246	0.00112	CcSEcCtD
Imipramine—Hyperhidrosis—Epirubicin—thyroid cancer	0.000245	0.00112	CcSEcCtD
Imipramine—Anxiety—Doxorubicin—thyroid cancer	0.000243	0.00111	CcSEcCtD
Imipramine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000243	0.00111	CcSEcCtD
Imipramine—Discomfort—Doxorubicin—thyroid cancer	0.000241	0.0011	CcSEcCtD
Imipramine—Anorexia—Epirubicin—thyroid cancer	0.000241	0.0011	CcSEcCtD
Imipramine—Dry mouth—Doxorubicin—thyroid cancer	0.000239	0.00109	CcSEcCtD
Imipramine—Confusional state—Doxorubicin—thyroid cancer	0.000236	0.00108	CcSEcCtD
Imipramine—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000234	0.00107	CcSEcCtD
Imipramine—Oedema—Doxorubicin—thyroid cancer	0.000234	0.00107	CcSEcCtD
Imipramine—Infection—Doxorubicin—thyroid cancer	0.000233	0.00106	CcSEcCtD
Imipramine—Shock—Doxorubicin—thyroid cancer	0.00023	0.00105	CcSEcCtD
Imipramine—Nervous system disorder—Doxorubicin—thyroid cancer	0.00023	0.00105	CcSEcCtD
Imipramine—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000229	0.00105	CcSEcCtD
Imipramine—Insomnia—Epirubicin—thyroid cancer	0.000229	0.00104	CcSEcCtD
Imipramine—Tachycardia—Doxorubicin—thyroid cancer	0.000228	0.00104	CcSEcCtD
Imipramine—Skin disorder—Doxorubicin—thyroid cancer	0.000227	0.00104	CcSEcCtD
Imipramine—Paraesthesia—Epirubicin—thyroid cancer	0.000227	0.00104	CcSEcCtD
Imipramine—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000226	0.00103	CcSEcCtD
Imipramine—Somnolence—Epirubicin—thyroid cancer	0.000225	0.00103	CcSEcCtD
Imipramine—Anorexia—Doxorubicin—thyroid cancer	0.000223	0.00102	CcSEcCtD
Imipramine—Dyspepsia—Epirubicin—thyroid cancer	0.000223	0.00102	CcSEcCtD
Imipramine—Decreased appetite—Epirubicin—thyroid cancer	0.00022	0.001	CcSEcCtD
Imipramine—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000218	0.000996	CcSEcCtD
Imipramine—Fatigue—Epirubicin—thyroid cancer	0.000218	0.000995	CcSEcCtD
Imipramine—Constipation—Epirubicin—thyroid cancer	0.000216	0.000987	CcSEcCtD
Imipramine—Insomnia—Doxorubicin—thyroid cancer	0.000212	0.000966	CcSEcCtD
Imipramine—Paraesthesia—Doxorubicin—thyroid cancer	0.00021	0.000959	CcSEcCtD
Imipramine—Feeling abnormal—Epirubicin—thyroid cancer	0.000209	0.000951	CcSEcCtD
Imipramine—Somnolence—Doxorubicin—thyroid cancer	0.000208	0.000949	CcSEcCtD
Imipramine—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000207	0.000944	CcSEcCtD
Imipramine—Dyspepsia—Doxorubicin—thyroid cancer	0.000206	0.00094	CcSEcCtD
Imipramine—Decreased appetite—Doxorubicin—thyroid cancer	0.000204	0.000928	CcSEcCtD
Imipramine—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000202	0.000922	CcSEcCtD
Imipramine—Fatigue—Doxorubicin—thyroid cancer	0.000202	0.000921	CcSEcCtD
Imipramine—Urticaria—Epirubicin—thyroid cancer	0.000201	0.000917	CcSEcCtD
Imipramine—Constipation—Doxorubicin—thyroid cancer	0.0002	0.000913	CcSEcCtD
Imipramine—Abdominal pain—Epirubicin—thyroid cancer	0.0002	0.000912	CcSEcCtD
Imipramine—Body temperature increased—Epirubicin—thyroid cancer	0.0002	0.000912	CcSEcCtD
Imipramine—Feeling abnormal—Doxorubicin—thyroid cancer	0.000193	0.00088	CcSEcCtD
Imipramine—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000191	0.000873	CcSEcCtD
Imipramine—ABCB1—lymph node—thyroid cancer	0.000191	0.00344	CbGeAlD
Imipramine—Urticaria—Doxorubicin—thyroid cancer	0.000186	0.000848	CcSEcCtD
Imipramine—Abdominal pain—Doxorubicin—thyroid cancer	0.000185	0.000844	CcSEcCtD
Imipramine—Body temperature increased—Doxorubicin—thyroid cancer	0.000185	0.000844	CcSEcCtD
Imipramine—Asthenia—Epirubicin—thyroid cancer	0.000182	0.000828	CcSEcCtD
Imipramine—Pruritus—Epirubicin—thyroid cancer	0.000179	0.000817	CcSEcCtD
Imipramine—Diarrhoea—Epirubicin—thyroid cancer	0.000173	0.00079	CcSEcCtD
Imipramine—Asthenia—Doxorubicin—thyroid cancer	0.000168	0.000766	CcSEcCtD
Imipramine—Dizziness—Epirubicin—thyroid cancer	0.000167	0.000763	CcSEcCtD
Imipramine—Pruritus—Doxorubicin—thyroid cancer	0.000166	0.000756	CcSEcCtD
Imipramine—Vomiting—Epirubicin—thyroid cancer	0.000161	0.000734	CcSEcCtD
Imipramine—Diarrhoea—Doxorubicin—thyroid cancer	0.00016	0.000731	CcSEcCtD
Imipramine—Rash—Epirubicin—thyroid cancer	0.00016	0.000728	CcSEcCtD
Imipramine—Dermatitis—Epirubicin—thyroid cancer	0.000159	0.000727	CcSEcCtD
Imipramine—Headache—Epirubicin—thyroid cancer	0.000159	0.000723	CcSEcCtD
Imipramine—Dizziness—Doxorubicin—thyroid cancer	0.000155	0.000706	CcSEcCtD
Imipramine—Nausea—Epirubicin—thyroid cancer	0.00015	0.000686	CcSEcCtD
Imipramine—Vomiting—Doxorubicin—thyroid cancer	0.000149	0.000679	CcSEcCtD
Imipramine—Rash—Doxorubicin—thyroid cancer	0.000148	0.000673	CcSEcCtD
Imipramine—Dermatitis—Doxorubicin—thyroid cancer	0.000147	0.000673	CcSEcCtD
Imipramine—Headache—Doxorubicin—thyroid cancer	0.000147	0.000669	CcSEcCtD
Imipramine—Nausea—Doxorubicin—thyroid cancer	0.000139	0.000634	CcSEcCtD
Imipramine—DRD2—Signaling Pathways—TERT—thyroid cancer	1.28e-05	0.00015	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—TERT—thyroid cancer	1.26e-05	0.000148	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—TERT—thyroid cancer	1.26e-05	0.000148	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—TERT—thyroid cancer	1.25e-05	0.000147	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—RXRA—thyroid cancer	1.25e-05	0.000147	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—TERT—thyroid cancer	1.25e-05	0.000147	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—TERT—thyroid cancer	1.24e-05	0.000145	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—TERT—thyroid cancer	1.23e-05	0.000145	CbGpPWpGaD
Imipramine—HTR1A—Signaling by GPCR—NRAS—thyroid cancer	1.23e-05	0.000144	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—HIF1A—thyroid cancer	1.22e-05	0.000144	CbGpPWpGaD
Imipramine—HTR2C—Signaling by GPCR—NRAS—thyroid cancer	1.22e-05	0.000144	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—RXRA—thyroid cancer	1.22e-05	0.000143	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.22e-05	0.000143	CbGpPWpGaD
Imipramine—CHRM3—Metabolism—PPARG—thyroid cancer	1.21e-05	0.000143	CbGpPWpGaD
Imipramine—HTR6—Signaling by GPCR—HRAS—thyroid cancer	1.21e-05	0.000143	CbGpPWpGaD
Imipramine—ADRA1D—Signaling by GPCR—KRAS—thyroid cancer	1.21e-05	0.000143	CbGpPWpGaD
Imipramine—HTR7—Signaling by GPCR—HRAS—thyroid cancer	1.21e-05	0.000143	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—HIF1A—thyroid cancer	1.2e-05	0.000142	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—HIF1A—thyroid cancer	1.2e-05	0.000141	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—HIF1A—thyroid cancer	1.2e-05	0.000141	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—TPR—thyroid cancer	1.19e-05	0.000141	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—HIF1A—thyroid cancer	1.19e-05	0.00014	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—HIF1A—thyroid cancer	1.18e-05	0.000139	CbGpPWpGaD
Imipramine—HTR6—GPCR downstream signaling—AKT1—thyroid cancer	1.18e-05	0.000139	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—HIF1A—thyroid cancer	1.18e-05	0.000139	CbGpPWpGaD
Imipramine—HTR7—GPCR downstream signaling—AKT1—thyroid cancer	1.18e-05	0.000139	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	1.18e-05	0.000138	CbGpPWpGaD
Imipramine—ADRA1B—Signaling by GPCR—NRAS—thyroid cancer	1.17e-05	0.000138	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—SLC5A5—thyroid cancer	1.16e-05	0.000136	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—BRAF—thyroid cancer	1.15e-05	0.000136	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—RXRA—thyroid cancer	1.15e-05	0.000135	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—BRAF—thyroid cancer	1.15e-05	0.000135	CbGpPWpGaD
Imipramine—CHRM4—Signaling by GPCR—HRAS—thyroid cancer	1.14e-05	0.000135	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—CCND1—thyroid cancer	1.14e-05	0.000134	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—CCND1—thyroid cancer	1.14e-05	0.000134	CbGpPWpGaD
Imipramine—CHRM4—GPCR downstream signaling—AKT1—thyroid cancer	1.11e-05	0.000131	CbGpPWpGaD
Imipramine—CYP3A7—Metabolism—PTGS2—thyroid cancer	1.11e-05	0.000131	CbGpPWpGaD
Imipramine—SLC22A2—Metabolism—PTGS2—thyroid cancer	1.11e-05	0.00013	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—BRAF—thyroid cancer	1.1e-05	0.000129	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—PTEN—thyroid cancer	1.1e-05	0.000129	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—PTEN—thyroid cancer	1.1e-05	0.000129	CbGpPWpGaD
Imipramine—CHRM5—Signaling by GPCR—HRAS—thyroid cancer	1.1e-05	0.000129	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.09e-05	0.000128	CbGpPWpGaD
Imipramine—DRD2—Signaling by GPCR—NRAS—thyroid cancer	1.08e-05	0.000127	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—CCND1—thyroid cancer	1.07e-05	0.000126	CbGpPWpGaD
Imipramine—HTR6—Signaling by GPCR—AKT1—thyroid cancer	1.07e-05	0.000126	CbGpPWpGaD
Imipramine—HTR7—Signaling by GPCR—AKT1—thyroid cancer	1.07e-05	0.000126	CbGpPWpGaD
Imipramine—CHRM5—GPCR downstream signaling—AKT1—thyroid cancer	1.07e-05	0.000125	CbGpPWpGaD
Imipramine—HTR2A—Signaling by GPCR—NRAS—thyroid cancer	1.06e-05	0.000125	CbGpPWpGaD
Imipramine—HRH1—Signaling by GPCR—NRAS—thyroid cancer	1.06e-05	0.000124	CbGpPWpGaD
Imipramine—HTR1A—Signaling by GPCR—KRAS—thyroid cancer	1.06e-05	0.000124	CbGpPWpGaD
Imipramine—CHRM1—Signaling by GPCR—NRAS—thyroid cancer	1.05e-05	0.000124	CbGpPWpGaD
Imipramine—CHRM3—Signaling by GPCR—NRAS—thyroid cancer	1.05e-05	0.000124	CbGpPWpGaD
Imipramine—HTR2C—Signaling by GPCR—KRAS—thyroid cancer	1.05e-05	0.000124	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—PPARG—thyroid cancer	1.04e-05	0.000123	CbGpPWpGaD
Imipramine—CHRM2—Signaling by GPCR—NRAS—thyroid cancer	1.04e-05	0.000122	CbGpPWpGaD
Imipramine—ADRA1A—Signaling by GPCR—NRAS—thyroid cancer	1.04e-05	0.000122	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—PTEN—thyroid cancer	1.04e-05	0.000122	CbGpPWpGaD
Imipramine—SLC22A1—Metabolism—PTGS2—thyroid cancer	1.03e-05	0.000122	CbGpPWpGaD
Imipramine—ADRA1D—Signaling by GPCR—HRAS—thyroid cancer	1.03e-05	0.000121	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—CCND1—thyroid cancer	1.03e-05	0.000121	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—PPARG—thyroid cancer	1.02e-05	0.00012	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—BRAF—thyroid cancer	1.01e-05	0.000119	CbGpPWpGaD
Imipramine—CHRM4—Signaling by GPCR—AKT1—thyroid cancer	1.01e-05	0.000119	CbGpPWpGaD
Imipramine—ADRA1B—Signaling by GPCR—KRAS—thyroid cancer	1.01e-05	0.000118	CbGpPWpGaD
Imipramine—ADRA1D—GPCR downstream signaling—AKT1—thyroid cancer	1e-05	0.000118	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—BRAF—thyroid cancer	9.97e-06	0.000117	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—BRAF—thyroid cancer	9.94e-06	0.000117	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—PTEN—thyroid cancer	9.92e-06	0.000117	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—BRAF—thyroid cancer	9.91e-06	0.000117	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—BRAF—thyroid cancer	9.88e-06	0.000116	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—NRAS—thyroid cancer	9.79e-06	0.000115	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—BRAF—thyroid cancer	9.79e-06	0.000115	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—NRAS—thyroid cancer	9.78e-06	0.000115	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—BRAF—thyroid cancer	9.76e-06	0.000115	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—RXRA—thyroid cancer	9.73e-06	0.000115	CbGpPWpGaD
Imipramine—CYP3A7—Metabolism—PTEN—thyroid cancer	9.68e-06	0.000114	CbGpPWpGaD
Imipramine—CHRM5—Signaling by GPCR—AKT1—thyroid cancer	9.68e-06	0.000114	CbGpPWpGaD
Imipramine—SLC22A2—Metabolism—PTEN—thyroid cancer	9.67e-06	0.000114	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—CCND1—thyroid cancer	9.66e-06	0.000114	CbGpPWpGaD
Imipramine—CHRM3—Metabolism—PTGS2—thyroid cancer	9.55e-06	0.000112	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	9.47e-06	0.000111	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—PTEN—thyroid cancer	9.32e-06	0.00011	CbGpPWpGaD
Imipramine—DRD2—Signaling by GPCR—KRAS—thyroid cancer	9.27e-06	0.000109	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—NRAS—thyroid cancer	9.24e-06	0.000109	CbGpPWpGaD
Imipramine—HTR2A—Signaling by GPCR—KRAS—thyroid cancer	9.13e-06	0.000107	CbGpPWpGaD
Imipramine—HRH1—Signaling by GPCR—KRAS—thyroid cancer	9.11e-06	0.000107	CbGpPWpGaD
Imipramine—ADRA1D—Signaling by GPCR—AKT1—thyroid cancer	9.1e-06	0.000107	CbGpPWpGaD
Imipramine—CHRM1—Signaling by GPCR—KRAS—thyroid cancer	9.08e-06	0.000107	CbGpPWpGaD
Imipramine—CHRM3—Signaling by GPCR—KRAS—thyroid cancer	9.05e-06	0.000106	CbGpPWpGaD
Imipramine—SLC22A1—Metabolism—PTEN—thyroid cancer	9.01e-06	0.000106	CbGpPWpGaD
Imipramine—HTR1A—Signaling by GPCR—HRAS—thyroid cancer	8.98e-06	0.000106	CbGpPWpGaD
Imipramine—CHRM2—Signaling by GPCR—KRAS—thyroid cancer	8.96e-06	0.000105	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—SLC5A5—thyroid cancer	8.94e-06	0.000105	CbGpPWpGaD
Imipramine—ADRA1A—Signaling by GPCR—KRAS—thyroid cancer	8.94e-06	0.000105	CbGpPWpGaD
Imipramine—HTR2C—Signaling by GPCR—HRAS—thyroid cancer	8.93e-06	0.000105	CbGpPWpGaD
Imipramine—SLC22A3—Metabolism—AKT1—thyroid cancer	8.88e-06	0.000105	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—NRAS—thyroid cancer	8.85e-06	0.000104	CbGpPWpGaD
Imipramine—HTR1A—GPCR downstream signaling—AKT1—thyroid cancer	8.73e-06	0.000103	CbGpPWpGaD
Imipramine—HTR2C—GPCR downstream signaling—AKT1—thyroid cancer	8.69e-06	0.000102	CbGpPWpGaD
Imipramine—ADRA1B—Signaling by GPCR—HRAS—thyroid cancer	8.55e-06	0.000101	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—KRAS—thyroid cancer	8.43e-06	9.92e-05	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—KRAS—thyroid cancer	8.42e-06	9.91e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—CCND1—thyroid cancer	8.42e-06	9.91e-05	CbGpPWpGaD
Imipramine—CYP2C18—Metabolism—AKT1—thyroid cancer	8.39e-06	9.88e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—CCND1—thyroid cancer	8.38e-06	9.85e-05	CbGpPWpGaD
Imipramine—CHRM3—Metabolism—PTEN—thyroid cancer	8.32e-06	9.79e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—NRAS—thyroid cancer	8.32e-06	9.79e-05	CbGpPWpGaD
Imipramine—ADRA1B—GPCR downstream signaling—AKT1—thyroid cancer	8.31e-06	9.78e-05	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—PTGS2—thyroid cancer	8.21e-06	9.66e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—PTEN—thyroid cancer	8.13e-06	9.56e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—PTEN—thyroid cancer	8.08e-06	9.51e-05	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—PTGS2—thyroid cancer	8.04e-06	9.46e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—CCND1—thyroid cancer	8.02e-06	9.43e-05	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—KRAS—thyroid cancer	7.95e-06	9.36e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling by GPCR—AKT1—thyroid cancer	7.93e-06	9.33e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—PPARG—thyroid cancer	7.89e-06	9.28e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling by GPCR—AKT1—thyroid cancer	7.89e-06	9.28e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling by GPCR—HRAS—thyroid cancer	7.88e-06	9.27e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling by GPCR—HRAS—thyroid cancer	7.76e-06	9.13e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling by GPCR—HRAS—thyroid cancer	7.74e-06	9.11e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—PTEN—thyroid cancer	7.74e-06	9.1e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling by GPCR—HRAS—thyroid cancer	7.72e-06	9.08e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—PPARG—thyroid cancer	7.7e-06	9.06e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling by GPCR—HRAS—thyroid cancer	7.69e-06	9.05e-05	CbGpPWpGaD
Imipramine—DRD2—GPCR downstream signaling—AKT1—thyroid cancer	7.67e-06	9.02e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling by GPCR—HRAS—thyroid cancer	7.62e-06	8.96e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—KRAS—thyroid cancer	7.62e-06	8.96e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling by GPCR—HRAS—thyroid cancer	7.6e-06	8.94e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling by GPCR—AKT1—thyroid cancer	7.55e-06	8.88e-05	CbGpPWpGaD
Imipramine—HTR2A—GPCR downstream signaling—AKT1—thyroid cancer	7.54e-06	8.87e-05	CbGpPWpGaD
Imipramine—HRH1—GPCR downstream signaling—AKT1—thyroid cancer	7.53e-06	8.85e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—RXRA—thyroid cancer	7.51e-06	8.84e-05	CbGpPWpGaD
Imipramine—CHRM1—GPCR downstream signaling—AKT1—thyroid cancer	7.5e-06	8.83e-05	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—TP53—thyroid cancer	7.49e-06	8.81e-05	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—TP53—thyroid cancer	7.48e-06	8.8e-05	CbGpPWpGaD
Imipramine—CHRM3—GPCR downstream signaling—AKT1—thyroid cancer	7.48e-06	8.8e-05	CbGpPWpGaD
Imipramine—CHRM2—GPCR downstream signaling—AKT1—thyroid cancer	7.41e-06	8.71e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—CCND1—thyroid cancer	7.39e-06	8.7e-05	CbGpPWpGaD
Imipramine—ADRA1A—GPCR downstream signaling—AKT1—thyroid cancer	7.38e-06	8.69e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—CCND1—thyroid cancer	7.27e-06	8.56e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—CCND1—thyroid cancer	7.26e-06	8.54e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—PPARG—thyroid cancer	7.26e-06	8.54e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—NRAS—thyroid cancer	7.25e-06	8.53e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—CCND1—thyroid cancer	7.23e-06	8.51e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—NRAS—thyroid cancer	7.21e-06	8.49e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—CCND1—thyroid cancer	7.21e-06	8.48e-05	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—HRAS—thyroid cancer	7.17e-06	8.43e-05	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—PTEN—thyroid cancer	7.16e-06	8.43e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—KRAS—thyroid cancer	7.16e-06	8.42e-05	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—HRAS—thyroid cancer	7.16e-06	8.42e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—CCND1—thyroid cancer	7.14e-06	8.4e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—PTEN—thyroid cancer	7.13e-06	8.39e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—CCND1—thyroid cancer	7.12e-06	8.38e-05	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—TP53—thyroid cancer	7.07e-06	8.32e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—PTEN—thyroid cancer	7.02e-06	8.26e-05	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—PTEN—thyroid cancer	7.01e-06	8.25e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—PTEN—thyroid cancer	7.01e-06	8.24e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—PTEN—thyroid cancer	6.98e-06	8.22e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling by GPCR—AKT1—thyroid cancer	6.96e-06	8.19e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—PTEN—thyroid cancer	6.96e-06	8.19e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—NRAS—thyroid cancer	6.9e-06	8.12e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—PTEN—thyroid cancer	6.89e-06	8.11e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—PTEN—thyroid cancer	6.87e-06	8.09e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling by GPCR—AKT1—thyroid cancer	6.85e-06	8.06e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling by GPCR—AKT1—thyroid cancer	6.83e-06	8.04e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling by GPCR—AKT1—thyroid cancer	6.81e-06	8.01e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling by GPCR—AKT1—thyroid cancer	6.79e-06	7.99e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—TP53—thyroid cancer	6.77e-06	7.96e-05	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—HRAS—thyroid cancer	6.76e-06	7.95e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling by GPCR—AKT1—thyroid cancer	6.72e-06	7.91e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling by GPCR—AKT1—thyroid cancer	6.71e-06	7.89e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—HRAS—thyroid cancer	6.47e-06	7.62e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—NRAS—thyroid cancer	6.37e-06	7.49e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—TP53—thyroid cancer	6.36e-06	7.49e-05	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—AKT1—thyroid cancer	6.33e-06	7.44e-05	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—AKT1—thyroid cancer	6.32e-06	7.44e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—NRAS—thyroid cancer	6.26e-06	7.37e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—NRAS—thyroid cancer	6.25e-06	7.35e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—KRAS—thyroid cancer	6.24e-06	7.34e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—NRAS—thyroid cancer	6.23e-06	7.33e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—NRAS—thyroid cancer	6.21e-06	7.31e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—KRAS—thyroid cancer	6.21e-06	7.3e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—PTGS2—thyroid cancer	6.21e-06	7.3e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—NRAS—thyroid cancer	6.15e-06	7.24e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—PPARG—thyroid cancer	6.15e-06	7.23e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—NRAS—thyroid cancer	6.13e-06	7.22e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—HRAS—thyroid cancer	6.09e-06	7.16e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—PTGS2—thyroid cancer	6.06e-06	7.13e-05	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—AKT1—thyroid cancer	5.97e-06	7.02e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—KRAS—thyroid cancer	5.94e-06	6.99e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—AKT1—thyroid cancer	5.72e-06	6.72e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—PTGS2—thyroid cancer	5.71e-06	6.71e-05	CbGpPWpGaD
Imipramine—CYP3A7—Metabolism—AKT1—thyroid cancer	5.58e-06	6.57e-05	CbGpPWpGaD
Imipramine—SLC22A2—Metabolism—AKT1—thyroid cancer	5.57e-06	6.56e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—TP53—thyroid cancer	5.55e-06	6.52e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—TP53—thyroid cancer	5.52e-06	6.49e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—KRAS—thyroid cancer	5.48e-06	6.45e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—PTEN—thyroid cancer	5.41e-06	6.37e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—KRAS—thyroid cancer	5.39e-06	6.34e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—KRAS—thyroid cancer	5.38e-06	6.33e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—AKT1—thyroid cancer	5.37e-06	6.32e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—KRAS—thyroid cancer	5.36e-06	6.31e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—KRAS—thyroid cancer	5.34e-06	6.29e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—HRAS—thyroid cancer	5.3e-06	6.24e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—KRAS—thyroid cancer	5.29e-06	6.23e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—PTEN—thyroid cancer	5.28e-06	6.21e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—TP53—thyroid cancer	5.28e-06	6.21e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—KRAS—thyroid cancer	5.28e-06	6.21e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—HRAS—thyroid cancer	5.28e-06	6.21e-05	CbGpPWpGaD
Imipramine—SLC22A1—Metabolism—AKT1—thyroid cancer	5.19e-06	6.11e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—HRAS—thyroid cancer	5.05e-06	5.94e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—PTEN—thyroid cancer	4.98e-06	5.86e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—TP53—thyroid cancer	4.87e-06	5.73e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—PTGS2—thyroid cancer	4.83e-06	5.69e-05	CbGpPWpGaD
Imipramine—CHRM3—Metabolism—AKT1—thyroid cancer	4.8e-06	5.64e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—TP53—thyroid cancer	4.79e-06	5.64e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—TP53—thyroid cancer	4.78e-06	5.62e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—TP53—thyroid cancer	4.77e-06	5.61e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—TP53—thyroid cancer	4.75e-06	5.59e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PPARG—thyroid cancer	4.74e-06	5.58e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—TP53—thyroid cancer	4.7e-06	5.53e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—TP53—thyroid cancer	4.69e-06	5.52e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—AKT1—thyroid cancer	4.68e-06	5.51e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—AKT1—thyroid cancer	4.66e-06	5.48e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—HRAS—thyroid cancer	4.66e-06	5.48e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—HRAS—thyroid cancer	4.58e-06	5.39e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—HRAS—thyroid cancer	4.57e-06	5.38e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—HRAS—thyroid cancer	4.56e-06	5.36e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—HRAS—thyroid cancer	4.54e-06	5.34e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—HRAS—thyroid cancer	4.5e-06	5.29e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—HRAS—thyroid cancer	4.49e-06	5.28e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—AKT1—thyroid cancer	4.46e-06	5.25e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—PTEN—thyroid cancer	4.22e-06	4.96e-05	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—AKT1—thyroid cancer	4.13e-06	4.86e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—AKT1—thyroid cancer	4.11e-06	4.84e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—AKT1—thyroid cancer	4.05e-06	4.76e-05	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—AKT1—thyroid cancer	4.04e-06	4.76e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—AKT1—thyroid cancer	4.04e-06	4.75e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—AKT1—thyroid cancer	4.02e-06	4.73e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—AKT1—thyroid cancer	4.01e-06	4.72e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—AKT1—thyroid cancer	3.97e-06	4.67e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—AKT1—thyroid cancer	3.96e-06	4.66e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PTGS2—thyroid cancer	3.73e-06	4.39e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PTEN—thyroid cancer	3.25e-06	3.83e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—AKT1—thyroid cancer	3.12e-06	3.67e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—AKT1—thyroid cancer	3.04e-06	3.58e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—AKT1—thyroid cancer	2.87e-06	3.37e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—AKT1—thyroid cancer	2.43e-06	2.86e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—AKT1—thyroid cancer	1.88e-06	2.21e-05	CbGpPWpGaD
